Showing 87 results
Story /- Media Release /NOYCIA recognizes excellence in Canadian oncology research as part of Novartis Canada’s commitment to reimagining medicineMontreal, QC, June 11, 2024 – Novartis Canada is pleased to announce the…
- Media Release /Psoriatic arthritis is a chronic, autoimmune disease form of arthritis that causes joint inflammation (swelling, pain, stiffness) and occurs with skin condition psoriasis. It can also affect the…
- Media Release /Approval is based on the two largest Phase III trials conducted in HS – SUNSHINE and SUNRISE – demonstrating the safety and efficacy of Cosentyx® in HS1HS is a chronic, immunological, inflammatory…
- Media Release /More than 90,000 Canadians—or one in 400 people across Canada—live with multiple sclerosis (MS),1 a neurodegenerative, chronic condition that affects the central nervous system.2Despite decades…
- Media Release /Montréal, QC, March 21, 2024 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by…
- Media Release /Montreal, Quebec, December 5, 2023 — Novartis Canada announces that Mark Vineis has been appointed to the role of Country President, effective as of January 1, 2024. Mark brings a wealth of…
- Media Release /Novartis has begun collaborating with seven clinics across the province to support the prevention, identification and management of atherosclerotic cardiovascular disease (ASCVD) In Ontario,…
Story /Novartis making history in blood cancer for decades
